By: Benzinga
March 21, 2013 at 07:53 AM EDT
ACADIA Presents Robust Phase III Results on Parkinson's Disease Psychosis Study with Pimavanserin, Shares Up 5% Pre-Market
ACADIA Pharmaceuticals (NASDAQ: ACAD ) announced that Jeffrey Cummings, M.D., Sc.D., Director of Cleveland Clinic Lou Ruvo Center for Brain Health, presented detailed results today from ACADIA's pivotal
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here